Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Corrona Rheumatoid Arthritis (RA) Drug Safety & Effectiveness Registry

Next Previous
Trial Profile

Corrona Rheumatoid Arthritis (RA) Drug Safety & Effectiveness Registry

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 17 Feb 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Abatacept (Primary) ; Rituximab (Primary) ; Tocilizumab (Primary) ; Tofacitinib (Primary) ; Adalimumab; Anakinra; Antirheumatics; Certolizumab pegol; Disease-modifying antirheumatics; Etanercept; Golimumab; Infliximab; Prednisone; Rituximab; Tumour necrosis factor inhibitors
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms CERTAIN; CorEvitas; CORRONA

Most Recent Events

  • 01 Feb 2025 Results (N= 3,481) assessing the effectiveness of tofacitinib versus tumor necrosis factor inhibitors and in those receiving tofacitinib as different lines of therapy in patients with rheumatoid arthritis were published in the Clinical Rheumatology
  • 09 Nov 2021 Results (n=175) assessing treatment outcomes over a 12-month period among patients prescribed TNFi therapies as a first targeted treatment and stratified according to MSRC results presented at the ACR Convergence 2021
  • 09 Nov 2021 Results of an analysis of Molecular Signature Response Classifier to predictive of inadequate response to TNFi presented at the ACR Convergence 2021

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top